This indicates that H3R levels are unlikely to underlie schizophrenia symptoms and may explain why it has proven challenging to develop medications targeting H3R to treat schizophrenia (Egan et al., 2013; Haig et al., 2014; Jarskog et al., 2015). This evidence concerns the gene HRH3 and schizophrenia.